Momenta, Sandoz Sue Teva Over Lovenox Generic
In a complaint filed Thursday in the U.S. District Court for the District of Massachusetts, Momenta and Sandoz assert that Teva's plans to market a generic enoxaparin drug product in the U.S. infringes two of Momenta's patents.
The patents are U.S. Patent Number 7,575,886, titled “Analysis of sulfated polysaccharides,” which generally relates...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login